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Abstract
The European Committee on Antimicrobial Susceptibility Testing
Subcommittee on Antifungal Susceptibility Testing (EUCAST-
AFST) has determined breakpoints for voriconazole against
Aspergillus spp. This Technical Note is based on the EUCAST
rationale document for voriconazole (available on the EUCAST
website: http://www.eucast.org). Voriconazole breakpoints are
based on epidemiological cut-off values, pharmacokinetic/pharma-
codynamic data and clinical experience. Breakpoints will be
reviewed regularly or when new data emerge.
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The European Committee on Antimicrobial Susceptibility
Testing-Subcommittee on Antifungal Susceptibility Testing
(EUCAST-AFST) has determined breakpoints for voriconazole
against Aspergillus spp. This Technical Note is based on a
EUCAST rationale document (available at: http://www.eucast.
org). The rationale documents include more detail and
published references related to the selection of EUCAST-
AFST breakpoints.
Voriconazole is a second-generation triazole agent with
broad-spectrum antifungal activity [1]. Voriconazole is
approved for treatment of a variety of fungal infections
including invasive aspergillosis. Breakpoints for Candida have
previously been established [2]. Voriconazole is available as an
intravenous formulation, an oral tablet and oral suspension.
The dosage that is currently licenced for adults receiving
intravenous therapy is 6 mg/kg intravenously, twice daily for
two dosages, followed by 4 mg/kg/day intravenously, twice
daily. The recommended oral regimen for adults is 400 mg
twice daily for two dosages followed by 200 mg twice daily.
The oral dosage can be increased to 300 mg twice daily if
clinically indicated. For children, a loading dose of 9 mg/kg
twice daily is recommended, followed by a maintenance dosage
of 8 mg/kg twice daily [3,4]. Therapeutic drug monitoring is
increasingly advocated in both children and adults, although
there is no regulatory requirement for this to be performed.
Trough concentrations of <1 mg/L have been associated with a
lower probability of clinical response and higher mortality in
adults and children, respectively, and is commonly found
despite standard dosing [5,6].
The pharmacokinetics of voriconazole are well character-
ized. In adults, the pharmacokinetics are highly variable but are
classical non-linear pharmacokinetics [7]. In children, there is
still considerable pharmacokinetic variability, but (pseudo)-
linear pharmacokinetics are observed. The point of transition
between seemingly linear pharmacokinetic behaviour and
classical non-linear pharmacokinetic occurs somewhere in
adolescence, and is difficult to predict on an individual basis.
The pharmacodynamics of voriconazole against Aspergillus have
been difficult to estimate. Most recently, a dynamic in vitro
model of the human alveolus suggested that area under the
curve : MIC and trough : MIC ratios of 32.1 and 1, respec-
tively, are associated with near-maximal antifungal activity [8].
These estimates are broadly concordant with estimates
obtained from other preclinical models that have used CLSI
methodology [9]; it should be noted, however, that MICs
determined using EUCAST methodology are usually one-
dilution higher compared with CLSI methodology.
The EUCAST breakpoints are based on a compilation of
microbiological, pharmacokinetic/pharmacodynamic data, and
clinical experience. Epidemiological cut-off values were deter-
mined from MIC values obtained from multiple European
laboratories, and are summarized in Table 1. Monte Carlo
simulation using a population pharmacokinetic model fitted to
human adult pharmacokinetic data [7] suggests that pharma-
codynamic targets associated with successful outcomes in
preclinical models can only be achieved for a suitably high
proportion of patients infected with an isolate with an MIC
 1 mg/L. The proportion of patients infected with an isolate
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases
RESEARCH NOTE MYCOLOGY
with an MIC 2 mg/L that have an area under the
curve : MIC > 32.1 is 67.5%, which then quickly drops to
unacceptably low levels for MICs of 4 mg/L and higher [8].
Data from multiple clinical trials suggest that Aspergillus is a
good target for voriconazole [10,11]. Unfortunately, however,
there are no specific MIC data (determined using EUCAST
methodology) that enable a relationship between MIC and
clinical outcome to be established. Consequently, the AFST
subcommittee has defined breakpoints in the following way:
susceptiblity  1, resistance >2 mg/L, providing adequate drug
exposure has been confirmed with therapeutic drug monitor-
ing. Isolates with an MIC of 2 mg/L are classified as ‘interme-
diate’ to indicate that dosage escalation may be required to
achieve the necessary drug exposure to maximize the
probability of a successful outcome. Furthermore, most
isolates with a CYP51A mutation have an MIC using EUCAST
methodology >1 mg/L. Therefore, if voriconazole therapy is
contemplated for isolates with an MIC of 2 mg/L, the
possibility of an underlying resistance mechanism should be
considered; this can be further investigated by testing against
other triazoles and/or referral to a specialized laboratory for
further genotypic and phenotypic characterization. If pheno-
typic resistance is confirmed or if an underlying molecular
mechanism of resistance is identified, then voriconazole should
not be used if there are suitable therapeutic alternatives.
EUCAST breakpoints only apply to licensed regimens. The
breakpoints will be reviewed when more data are available for
Aspergillus species that were not assigned breakpoints during
the present review, when there are clinical data for isolates
with MIC values outside the wild-type distribution or when
there are further data related to optimal drug exposures.
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